Qiagen N.V. (NYSE:QGEN) Given Average Rating of “Hold” by Analysts

Shares of Qiagen N.V. (NYSE:QGEN) have been given an average rating of “Hold” by the twelve research firms that are covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $55.1988.

A number of research analysts have issued reports on QGEN shares. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. JPMorgan Chase & Co. boosted their price objective on shares of Qiagen from $55.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Deutsche Bank Aktiengesellschaft downgraded shares of Qiagen from a “buy” rating to a “hold” rating and upped their price objective for the company from $52.00 to $54.00 in a research note on Thursday, January 22nd. UBS Group set a $52.00 target price on shares of Qiagen in a research note on Monday. Finally, Citigroup cut their price target on Qiagen from $55.40 to $55.00 and set a “neutral” rating for the company in a report on Friday, February 6th.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $50.90 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.30 and a current ratio of 3.90. The business’s fifty day moving average price is $49.77 and its two-hundred day moving average price is $49.61. The stock has a market cap of $10.75 billion, a PE ratio of 25.25, a price-to-earnings-growth ratio of 2.49 and a beta of 0.67. Qiagen has a one year low of $39.61 and a one year high of $57.81.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. The company had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.61 earnings per share. On average, analysts forecast that Qiagen will post 2.26 EPS for the current fiscal year.

Hedge Funds Weigh In On Qiagen

Large investors have recently added to or reduced their stakes in the business. Boston Partners purchased a new stake in Qiagen in the 3rd quarter valued at about $179,450,000. Norges Bank acquired a new stake in shares of Qiagen in the fourth quarter worth approximately $166,500,000. Dimensional Fund Advisors LP purchased a new stake in Qiagen in the third quarter valued at approximately $58,079,000. Allianz Asset Management GmbH increased its position in Qiagen by 366.7% during the second quarter. Allianz Asset Management GmbH now owns 994,697 shares of the company’s stock worth $47,470,000 after purchasing an additional 781,561 shares during the last quarter. Finally, Deutsche Bank AG increased its position in Qiagen by 9.7% during the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after purchasing an additional 697,342 shares during the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.